| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Jenna Brashear
Cynthia McLaughlin
Cynthia McLaughlin
Omar Beirat
| Share Statistics | ZYBT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $62.3 | $579.1 | 18% |
|
| Shares Out (Mil) | 6.8 | 43.0 | 16% |
|
| Institutional Ownership | na | 84.3% | na |
|
| Float (Mil) | 6.3 | 46.8 | 14% |
|
| Beta | na | 0.62 | na |
|
| Avg Daily Volume (000s) | 23,362 | 285 | 99% |
|
| Price Change (52-week) |
(76.5%) | 63.8% | 7% |
|
| Growth | ZYBT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (1.4%) | na |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ZYBT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $17 | $272 | 12% |
|
| Net Income (TTM) (Mil) | ($10) | ($11) | 29% |
|
| EPS (TTM) | ($0.211) | ($0.500) | 33% |
|
| Operating Cash Flow (TTM) (Mil) | $2 | ($6) | 34% |
|
| Net Cash Flow (TTM) (Mil) | $4 | $4 | 52% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $7 | 18% |
|
| Enterprise Value (Q1) (Mil) | $44 | $522 | 15% |
|
| Valuation | ZYBT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.75 | 2.73 | 46% |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | ZYBT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 20.5% | 65.9% | 22% |
|
| Net Margin | (60.0%) | 0.7% | 10% |
|
| ROA | (15.4%) | (24.6%) | 22% |
|
| ROE | (26.7%) | (19.7%) | 21% |
|
| Liabilities to Assets | 29.7% | 35.5% | 21% |
|
| F-Score | 2 | 3 | 7% |
|
Zhengye Biotechnology Holding Limited did not pass any screens on 7/31/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
